Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

NCT06924606 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Advanced NSCLC

Interventions

DRUG: JS207 injection +docetaxel
DRUG: JS207 injection +JS004 injection
DRUG: JS207 injection

Sponsor

Shanghai Junshi Bioscience Co., Ltd.